Veradigm Inc. (MDRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,503 | 577 | 588 | - | - | - | 445 | 583 |
| Operating profit | $m | -27 | 26 | ||||||
| Net profit | $m | 700 | 134 | -86 | - | - | - | -32 | 39 |
| EPS reported | $ | -0.67 | 0.32 | ||||||
| Operating cashflow per share | $ | 0.90 | 0.90 | ||||||
| Capex per share | $ | 0.25 | 0.25 | ||||||
| FCF per share | $ | 0.65 | 0.65 | ||||||
| Free cash flow | $m | 83 | 87 | ||||||
| Net debt | $m | -246 | 0 | ||||||
| Book value equity | $m | 1,018 | - | ||||||
| Book value per share | $ | 7.89 | 7.89 | ||||||
| Number of shares | m | 128.9 | 128.9 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 5.02 | ||||||
| P/B LTM | x | 2.23 | 0.61 | ||||||
| P/S LTM | x | 3.87 | 1.39 | ||||||
| P/FCF LTM | x | 27.30 | 9.79 | ||||||
| EV/EBITDA LTM | x | 35.03 | 10.06 | ||||||
| EV/Sales LTM | x | 3.48 | 1.00 | ||||||
| Earnings Yield LTM | % | -3.80% | +19.92% | ||||||
| FCF Yield | % | +3.66% | +10.71% | ||||||
| Quality | |||||||||
| ROE | % | -8.50% | -7.13% | ||||||
| ROIC | % | -0.66% | -0.66% | ||||||
| Operating margin | % | -4.61% | -4.61% | ||||||
| Gross margin | % | +52.45% | +52.45% | ||||||
| FCF/Sales | % | +14.17% | +14.17% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +1.83% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.38 | - | ||||||
| Net Debt/EBITDA | x | -3.89 | -3.89 | ||||||
| EBIT/Net interest | x | -4.27 | -4.27 | ||||||
| Net debt/market cap | % | +8.81% | +25.39% | ||||||
| Net debt/Equity | x | -0.24 | - | ||||||
| Gross debt/equity | x | 0.22 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Veradigm Inc. is a global healthcare technology enterprise that delivers cutting-edge information technology platforms to a diverse client base, including healthcare providers, health plans (payers), and biopharmaceutical companies, operating across the United States and various international markets. For healthcare providers, the company offers a suite of integrated solutions designed to optimize operations. These include Practice Management software, AI-driven Patient Scheduling tools, and systems for Electronic Statements and Payments. Veradigm also provides comprehensive revenue cycle management, encompassing specialized services and a dedicated clearinghouse to streamline financial workflows. Furthermore, their electronic health records (EHR) portfolio features advanced options like ePrescribe with EPCS, Veradigm HER, and Practice Fusion HER, complemented by a robust Patient Engagement Platform. The firm extends its offerings to network partners through a variety of connectivity solutions. These comprise API integration tools such as Veradigm Connect and Veradigm App Expo, a Diagnostic Ordering and Resulting Network, a Channel Partner Program, and Veradigm ePrescribe Enterprise. Health plans and payers benefit from Veradigm's specialized solutions, which include sophisticated risk adjustment tools like Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics. They also provide quality management systems, including quality analytics and integrated risk adjustment and quality management features. Data exchange and coding solutions, such as eChart Courier, eChart Coder, and eChart Integration and Analytics, further enhance efficiency. Additionally, Veradigm offers provider engagement platforms like Veradigm Payer Insights and the comprehensive Veradigm Payerpath suite. For the biopharma sector, Veradigm supplies valuable real-world data solutions, including extensive health datasets and specialized registries for cardiology and metabolic conditions. This is coupled with real-world evidence platforms, such as the Real World Evidence Analytics Platform. Therapy-focused data is available for key areas like cardiovascular, central nervous system, metabolic, and immunology. The company also delivers Digital Health Media solutions. Established in 1986 and headquartered in Chicago, Illinois, Veradigm Inc. was previously known as Allscripts Healthcare Solutions, Inc., before rebranding to its current name in January 2023.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free